Oncopathology - dawn of a new era
- Authors: Badve S.S.1, Gokmen-Polar Y.1
-
Affiliations:
- Indiana University
- Issue: Vol 1, No 1 (2018)
- Pages: 12-17
- Section: Leading article
- Published: 18.02.2018
- URL: https://oncopathology.abvpress.ru/2618-7019/article/view/708416
- DOI: https://doi.org/10.17650/2619-7019-2018-1-1-12-17
- EDN: https://elibrary.ru/NDCTOI
- ID: 708416
Cite item
Full Text
Abstract
Pathology by definition is the study of disease originating from the Greek “pathos” - “suffering” and “ology” - “study of”. In medicine, it is the branch of medical science that studies the causes and effects of diseases. Advances in the field of pathology first led to the establishment of anatomic pathology as a separate discipline. Further advances have made it necessary for pathologists to sub-specialize in the field of oncology. Tumor pathology is no longer the discipline that recognizes the presence of a tumor and determines the morphological/patho-logical characteristics of the tumor. Advances in genomic technologies have resulted in better understanding of the biology of tumors forming the basis of “oncopathology” (“onco” originating from the Greek “onkos” - tumor). Oncopathology combines precision oncology with the predictive pathology tailored for each individual, as it is key to translate the prognostic biomarkers into predictive biomarkers to improve the efficacy of clinical therapeutics in the management of cancer. This article highlights the recent developments and underlines the needfor the discipline of oncopathology (and a journal devoted to it).
About the authors
S. S. Badve
Indiana University
Email: abv@abvpress.ru
USA
Y. Gokmen-Polar
Author for correspondence.
Email: abv@abvpress.ru
References
- Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9. PMID: 28094848. DOI: 10.3322/ caac.21388.
- Brem S., Cotran R., Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48(2):347-56. PMID: 4347034.
- Folkerth R.D. Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res 2004;117:79-95. PMID: 15015553.
- Jain R., Griffith B., Alotaibi F. et al. Glioma angiogenesis and perfusion imaging: understanding the relationship between tumor blood volume and leakiness with increasing glioma grade. AJNR Am J Neuroradiol 2015;36(11):2030-5. PMID: 26206809. doi: 10.3174/ajnr. A4405.
- Adams S., Gray R.J., Demaria S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32(27):2959-66. PMID: 25071121. doi: 10.1200/JCO.2013.55.0491.
- Hendry S., Salgado R., Gevaert T. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017;24(6):311-35. PMID: 28777143. DOI: 10.1097/ PAP.0000000000000161.
- Galon J., Mlecnik B., Bindea G. et al. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 2014;232(2):199-209. PMID: 24122236. DOI: 10.1002/ path.4287.
- Wolff A.C., Hammond M.E., Hicks D.G. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997-4013. PMID: 24101045. DOI: 10.1200/ JCO.2013.50.9984.
- Bang Y.J., Van Cutsem E., Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376(9742):687-97.
- Van Cutsem E., Bang Y.J., Feng-Yi F. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18(3):476-84. PMID: 25038874. doi: 10.1007/s10120-014-0402-y.
- Lin G., Fan X., Zhu W. et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. On-cotarget 2017;8(48):83986-94. PMID: 29137398. doi: 10.18632/onco-target.20233.
- Kulangara K., Hanks D.A., Waldroup S. et al. Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immu-nohistochemistry assay PD-L1 IHC 22C3 pharmDx. American Society of Clinical Oncology Annual Meeting 2017, Chicago, IL.
- Raymond V.M., Gray S.W., Roychowd-hury S. et al. Germline findings in tumor-only sequencing: points to consider for clinicians and laboratories. J Natl Cancer Inst 2015;108(4). pii: djv351. PMID: 26590952. doi: 10.1093/jnci/djv351.
- Kamps R., Brandao R.D., Bosch B.J. et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification.Int J Mol Sci 2017;18(2):E308. PMID: 28146134. doi: 10.3390/ijms18020308.
- Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017;102(6):934-41. PMID: 28795401. doi: 10.1002/cpt.814.
- Sosman J.A., Kim K.B., Schuchter L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8): 707-14. PMID: 22356324. doi: 10.1056/NEJMoa1112302.
- Hyman D.M., Puzanov I., Subbiah V. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373(8):726-36. PMID: 26287849. doi: 10.1056/NEJ-Moa1502309.
- Louis D.N., Perry A., Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131(6):803-20. PMID: 27157931. doi: 10.1007/s00401-016-1545-1.
- Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013;5(209):209ra153. PMID: 24174329. doi: 10.1126/scitranslmed.3006802.
- Rotow J., Bivona T.G. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17(11):637-58. PMID: 29068003. doi: 10.1038/nrc.2017.84.
- Odogwu L., Mathieu L., Goldberg K.B. et al. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation. Oncologist 2017: theoncologist.2017-0425. PMID: 29242281. doi: 10.1634/theoncologist.2017-0425.
- Mayo-de-Las-Casas C., Garzon Ibanez M., Jordana-Ariza N. et al. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Rev Mol Diagn 2018;18(1): 35-45. PMID: 29172773. doi: 10.1080/14737159.2018.1407243.
- Chaudhuri A.A., Chabon J.J., Lovejoy A.F. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 2017;7(12):1394-403. PMID: 28899864. doi: 10.1158/2159-8290.CD-17-0716.
- Sparano J.A., O'Neill A., Alpaugh K. et al. Circulating tumor cells (CTCs) 5 years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. San Antonio Breast Cancer Symposium 2017.
- Alix-Panabieres C., Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6(5):479-91. PMID: 26969689. doi: 10.1158/2159-8290.CD-15-1483.
Supplementary files
